VIR - Vir Biotechnology Inc

VIR - Vir Biotechnology Inc

https://www.vir.bio

Buy Momentum: Bearish

Recent News

Powered by Alpha Vantage

This Eli Lilly Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Wednesday - Amer Sports ( NYSE:AS ) , Eli Lilly ( NYSE:LLY )

Benzinga • 2 weeks, 4 days ago • score: 0.33

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Scotiabank analyst Nicholas Yulico upgraded Prologis, Inc.

Vir ( VIR ) Q2 Revenue Drops 61%

Motley Fool • 1 month, 1 week ago • score: 0.10

Vir Biotechnology ( NASDAQ:VIR ) , a clinical-stage biotech focused on infectious diseases and immuno-oncology, reported results on August 6, 2025. The company announced a net loss per share of $ ( 0.80 ) ( GAAP ) . Revenue ( GAAP ) also fell short, reaching only $1.2 million against estimates of ...

Vir Biotechnology, Inc. ( VIR ) Reports Q2 Loss, Lags Revenue Estimates

Zacks Commentary • 1 month, 1 week ago • score: 0.04

Vir Biotechnology (VIR) delivered earnings and revenue surprises of -11.11% and -84.12%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Vir Biotechnology ( VIR ) Soars 11.9%: Is Further Upside Left in the Stock?

Zacks Commentary • 2 months ago • score: 0.19

Vir Biotechnology (VIR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Vir Biotechnology, Inc. ( VIR ) Reports Q1 Loss, Lags Revenue Estimates

Zacks Commentary • 4 months, 1 week ago • score: -0.03

Vir Biotechnology (VIR) delivered earnings and revenue surprises of -6.02% and 84.51%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. The company is headquartered in San Francisco, California.

52W High

$14.45

52W Low

$4.16

MA Status:

50D: Above 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.28

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

4.36

EV/EBITDA (<8 favorable)

0.90

EV/Revenue (<3 favorable)

15.86

P/S (TTM) (<3 favorable)

38.53

P/B (<3 favorable)

0.77

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

10.49%

Institutions (25–75% balanced)

81.80%

Shares Outstanding

138,916,000

Float

94,577,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

19,000,000

Gross Profit (TTM)

-467,601,984

EPS (TTM)

-4.01

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-97.68%

ROE (TTM) (>15% strong)

-0.46%

EPS YoY (Quarterly) (>10% good)

0.59

Revenue YoY (Quarterly) (>8% good)

-0.61

Momentum

Bearish momentum

Value

0.1041

Previous

0.1259

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025